Navigation Links
Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Date:5/28/2009

SAN MATEO¿ Calif.¿ May 28 /PRNewswire/ -- Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France.

Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the Pre-RELAX-AHF study, will present the main results from the multicenter, international Pre-RELAX-AHF study at 8:30 a.m. CET on Sunday, May 31, at the Judges' Choice oral abstracts session. Dr. Metra will also present additional analyses of the Pre-RELAX-AHF study during a late-breaking clinical trials session at 11:15 a.m. CET on Monday, June 1. Five posters from the Pre-RELAX-AHF study will also be presented from 8:30 a.m. to 12:30 p.m. CET on Monday, June 1.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.

About Corthera

Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com. <
'/>"/>

SOURCE Corthera Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications ... months ended June 30, 2015. "Our ... growth, as revenues increased 47 percent year-over-year and ... Officer Michael Davin. "While our international results reflected ...
(Date:7/28/2015)... CRY ), a leading medical device and tissue ... today its results for the second quarter and first ... Chairman, President and Chief Executive Officer, said, "During the ... with solid progress on several of our top organizational ... a direct sales model in France, advancing our strategic ...
(Date:7/28/2015)... July 28, 2015 ANI Pharmaceuticals, Inc. (NASDAQ: ... to release its second quarter and year-to-date 2015 financial ... of the U.S. financial markets. The earnings press release ... the Company,s website, www.anipharmaceuticals.com . ... and Charlotte C. Arnold , Vice President and ...
Breaking Medicine Technology:Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 2Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 3Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 4Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 5Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 6Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 7Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 8Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 9Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 10Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 11Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 12Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 13CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2
... Thousands of jobs in Texas supported by the ... – such as imposing new taxes in the Medicare ... From research to technical work, manufacturing to ... care services, the biopharmaceutical sector supports a broad array ...
... REDWOOD CITY, Calif. and SAO PAULO, Sept. 27, 2011 ... Raizen Energia S.A. today announced the signing of a ... ethanol process with enhanced performance economics. Raizen is Brazil,s ... the terms of the agreement, Raizen and Codexis will ...
Cached Medicine Technology:Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 3Codexis, Raizen to Develop First Generation Ethanol 2Codexis, Raizen to Develop First Generation Ethanol 3
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard Scientifics, Inc. (NYSE:SFE) ... from time to time and depending on market conditions, to repurchase shares of ... Repurchases will be made in open market or privately negotiated transactions in compliance ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... GA (PRWEB) , ... July 28, 2015 , ... ... been chosen as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual ... row by hundreds of her esteemed colleagues and peers in the metro area as ...
(Date:7/28/2015)... , ... July 28, 2015 , ... A new study ... Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option for ... two months of regular HBOT sessions, at least five per week, patients experienced a ...
(Date:7/28/2015)... Irvine, CA (PRWEB) , ... July 28, 2015 ... ... risk of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of ... clinical cardiology is the identification of individuals with active yet undetected sub-clinical disease, ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... COLUMBUS, Ohio, Jan. 19 Abbott ... voluntary recall of,ZonePerfect(R) Chocolate Peanut Butter bars, ZonePerfect(R) ... in response to the widening,recall involving peanut butter ... America (PCA). PCA was one of the ...
... with early-stage lung cancer are not seen when patients ... the January issue of Archives of Surgery , ... more deaths in the United States than any other ... resectionor surgery to remove a portion of the lungprovides ...
... setting, study finds , , MONDAY, Jan. 19 (HealthDay News) ... on the rise among American children, a new report ... the bacteria Staphylococcus aureus -- referred to ... methicillin -- are moving beyond the traditional confines of ...
... /PRNewswire-FirstCall/ - The Board of Directors of NUCRYST ... B. Holtz as interim President and Chief Executive ... Chairman, effective immediately. Mr. Holtz replaces Thomas E. ... Officer. Mr. Carragher, currently lead director of NUCRYST, ...
... Aribex, Inc., a world leader in handheld x-ray ... second U.S. patent for its NOMAD Handheld X-ray System. ... concept of having all components of the x-ray system ... development of the world,s first handheld x-ray system. Aribex ...
... ethnicity, types of seafood consumed , , MONDAY, Jan. 19 (HealthDay ... for a living, and her ethnicity may all be ... new survey says. , The report, published in the January ... in coastal areas in the Northeastern United States had ...
Cached Medicine News:Health News:Abbott Nutrition Announces Voluntary Recall of ZonePerfect(R) Chocolate Peanut Butter Bars, ZonePerfect(R) Peanut Toffee Bars and NutriPals(TM) Peanut Butter Chocolate Bars in U.S., Mexico, New Zealand and Singapore 2Health News:Study examines racial disparities in survival among patients diagnosed with lung cancer 2Health News:MRSA Infections Spreading to Kids in Community 2Health News:MRSA Infections Spreading to Kids in Community 3Health News:NUCRYST appoints interim CEO 2Health News:NUCRYST appoints interim CEO 3Health News:Aribex(R) Awarded Patents for Handheld X-ray 2Health News:Women in Coastal Areas Have Higher Mercury Levels 2
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
Medicine Products: